Zobrazeno 1 - 10
of 44
pro vyhledávání: '"35"'
Autor:
Atsushi Sato, Yasushi Tsuji, Takahide Sasaki, Shintaro Nakano, Susumu Sogabe, Atsushi Ishiguro, Hiroshi Nakatsumi, Satoshi Yuki, Yoshito Komatsu, Masayoshi Dazai, Osamu Muto, Yuh Sakata, Hiroyuki Okuda, Kentaro Sawada, Kazuaki Harada, Naoya Sakamoto, Mari Sekiguchi, Yasuyuki Kawamoto, Michio Nakamura, Yoshiaki Shindo
Publikováno v:
Journal of Clinical Oncology. 39:217-217
217 Background: Ramucirumab (RAM) is a fully human IgG1 monoclonal vascular endothelial growth factor receptor-2 (VEGFR-2) antibody. The RAINBOW trial showed RAM plus paclitaxel (PTX) increased overall survival (OS) compared with PTX alone for advanc
Autor:
Vicente Alonso, Ana Herrero, Teresa Puertolas, Eduardo Polo Marques, Juan Lao Romera, Beatriz Eizaguirre, Esther Millastre, Julia Madani, Antonio Antón
Publikováno v:
Journal of Clinical Oncology. 35:e17023-e17023
e17023 Background: Combination of radiotherapy plus platinum-based chemotherapy (RT-CT) is considered the standard treatment in LACC. The risk of recurrence after local treatment is around 50-70%. The role of angiogenesis in tumor progression has bee
Autor:
Apurvasena Parikh, Colin D. Weekes, Monica Motwani, Daniel Morgensztern, Huibin Yue, Edward B. Reilly, John Nemunaitis, Todd M. Bauer, Ramesh K. Ramanathan, Daniel E. H. Afar, Rebecca S. Heist, Karen Kelly, Eric Angevin, John H. Strickler, Louie Naumovski
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 36, iss 33
Strickler, JH; Weekes, CD; Nemunaitis, J; Ramanathan, RK; Heist, RS; Morgensztern, D; et al.(2018). First-in-Human Phase I, Dose-Escalation and-Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2018787697. doi: 10.1200/jco.2018.78.7697. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/8bt41691
Strickler, JH; Weekes, CD; Nemunaitis, J; Ramanathan, RK; Heist, RS; Morgensztern, D; et al.(2018). First-in-Human Phase I, Dose-Escalation and-Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2018787697. doi: 10.1200/jco.2018.78.7697. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/8bt41691
Purpose This first-in-human study evaluated telisotuzumab vedotin (Teliso-V), formerly called ABBV-399, an antibody–drug conjugate of the anti–c-Met monoclonal antibody ABT-700 and monomethyl auristatin E. Materials and Methods For dose escalatio
Autor:
Prateek Sharma, Bruce F. Kimler, Carola M. Zalles, Qamar J. Khan, Trina Metheny, Carol J. Fabian, S. Baxa
Publikováno v:
Journal of Clinical Oncology. 27:1507-1507
1507 Background: The lignans enterolactone and enterodiol are derived from the action of gut bacteria on ingested secoisolariciresinol diglycoside (SDG) which is commonly found in flaxseed. Enterolactone and enterodiol are thought to impair mammary c
Publikováno v:
Journal of Clinical Oncology. 27:6581-6581
6581 Background: Bevacizumab, a recombinant antibody which neutralizes vascular endothelial growth factor (VEGF), has been approved for the treatment of advanced non-small cell lung cancer (NSCLC). Costs of novel anticancer medications such as bevaci
Autor:
Ursula A. Matulonis, J. Michels, C. Sexton, Robert P. Edwards, Hal W. Hirte, G. Michelson, P. Hoskins, A. Husain, William McGuire
Publikováno v:
Journal of Clinical Oncology. 27:5559-5559
5559 Background: Voreloxin is a naphthyridine analog that intercalates DNA and inhibits topoisomerase II, inducing apoptosis. Clinical activity has been observed in ovarian cancer and AML. Results are reported from a fully enrolled phase II study of
Autor:
T. Delozier, Thomas Bachelot, Gilles Freyer, J. F. Geay, Pascale Romestaing, D. Mille, Marc Debled, J. Cretin, E. Blot, Eric Pujade-Lauraine, J-M Ferrero
Publikováno v:
Journal of Clinical Oncology. 24:565-565
565 Background: in vitro and in vivo studies suggest that COX-2 inhibitors have proper antitumor effect and could enhance the activity of aromatase inhibitors (AI). Methods: PM first-line MBC pts without previous adjuvant AI were randomized to receiv
Publikováno v:
Journal of Clinical Oncology. 39:e15541-e15541
e15541 Background: Apolipoprotein b (apob), apolipoprotein a1 (apoa1), and lactate dehydrogenase (LDH) levels are circulating biomarkers that relate to tumor inflammation. This study aimed to evaluate the prognostic role of apob/apoa1 and LDH in rese
Autor:
David M. Gershenson, Virginia Bayer, Neil S. Horowitz, Alexis Rabbit, Susana M. Campos, Shannon N. Westin, Lone Ottesen, Anil K. Sood, Pamela T. Soliman, Ying Yuan, Robert L. Coleman, Sobiya Tukdi, Alexi A. Wright, Panagiotis A. Konstantinopoulos, Gordon B. Mills, Robert Godin, Karen H. Lu, Charles F Levenback, Bryan Fellman, Joyce F. Liu
Publikováno v:
Journal of Clinical Oncology. 39:5505-5505
5505 Background: Wee1 phosphorylates and inhibits cyclin-dependent kinases 1 and 2 and is involved in regulation of the intra-S and G2/M cell cycle checkpoint arrest for premitotic DNA repair. The Wee1 inhibitor, adavosertib, has demonstrated activit
Publikováno v:
Journal of Clinical Oncology. 39:TPS184-TPS184
TPS184 Background: The combination of pembro, an anti–PD-1 antibody, added to enza, a nonsteroidal antiandrogen agent, has shown antitumor activity in abiraterone-resistant metastatic castration-resistant prostate cancer (mCRPC) in the KEYNOTE-365